Effects of SK &amp; F 92657 on the superficial hand veins and forearm arterioles of man [proceedings]

Collier, Joe; Pitcher, DW

doi:10.1111/j.1365-2125.1980.tb04859.x

Cited by 5 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collier et al [236] investigated the effects of the a-and ,-adrenoceptor blocking drug labetalol on superficial hand veins and found that it inhibited in a competitive manner the constrictor effects of locally infuised noradrenaline as well as the dilator effects of the P-adrenoceptor agonist isoprenaline (but not other dilator drugs acting via different mechanisms such as acetylcholine, histamine, and bradykinin) locally infused into veins preconstricted by 5-hydroxytryptamine. Collier & Pitcher [237] found that SK&F 92657, a j-adrenoceptor blocking drug with hydralazine-like ancillary properties, reduced the dilator effects of isoprenaline infused into superficial hand veins and the brachial artery, as expected for a 0-adrenoceptor blocking drug. In addition, however, it also had a direct dilator effect when infused into the brachial artery, but not on superficial hand veins.…”

Section: Effects On /3-adrenoceptorsmentioning

confidence: 99%

Clinical pharmacology, physiology and pathophysiology of superficial veins‐2.

Aellig

1994

Brit J Clinical Pharma

View full text Add to dashboard Cite

Section: Effects On /3-adrenoceptorsmentioning

confidence: 99%

Clinical pharmacology, physiology and pathophysiology of superficial veins‐2.

Aellig

1994

Brit J Clinical Pharma

View full text Add to dashboard Cite

Prizidilol, a combined vasodilatory and β-adrenoceptor blocking drug, in primary hypertension

Karlberg

Larsson

Öhman

et al. 1983

Eur J Clin Pharmacol

View full text Add to dashboard Cite

After an initial placebo period of four weeks 24 patients with primary hypertension were treated with prizidilol, a hydrazinopyridazine derivative with combined vasodilator and non-selective beta-adrenoceptor blocking actions, for a dose titration period of 14 weeks. Prizidilol 200 to 800 mg was given once daily to achieve a target supine diastolic blood pressure (BP) less than 90 mmHg. Supine and standing BP recorded 24-27 h after drug intake decreased from 172 +/- 17/106 +/- 6 mmHg (mean +/- SD) and 167 +/- 18/111 +/- 8 mmHg, respectively, after placebo to 159 +/- 16/99 +/- 8 and 154 +/- 18/101 +/- 9 mmHg after active treatment for six weeks (mean dose 447 mg), and to 154 +/- 16/97 +/- 7 and 148 +/- 14/97 +/- 7 mmHg after treatment for 14 weeks (mean dose 687 mg/day). A slight reduction in HR was seen after treatment for six weeks and in plasma renin activity and urinary methoxycatecholamine excretion after treatment for 14 weeks. A sustained decrease in BP was observed for 10 h after prizidilol 800 mg (n = 9), with a maximum antihypertensive effect (mean reduction in supine BP 33/18 mmHg) 2.5 h after dosing, which coincided with the mean peak plasma concentration. The plasma elimination half-life of the drug was 3.9 h (range 2.0-8.9 h). Changing to a twice daily regimen in 17 patients (mean daily dose 748 mg at six months) did not produce any further reduction in the BP (recorded 12-15 h after dosing) as compared to the once daily regimen at 14 weeks.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension

Lüscher

Havelka

Greminger

et al. 1982

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The antihypertensive effect of a new vasodilator with betablocking properties (SK & F 92657) was investigated in 10 patients with mild to moderate essential hypertension. After a mean treatment period of 26,5 weeks (6,5-49 weeks) blood pressure was significantly reduced, from 168 +/- 22/106 +/- 6 mmHg to 144 +/- 19/94 +/- 12 mmHg (p less than 0.05 and 0.025). The mean dose was 410 mg (100-700 mg). Heart rate decreased slightly from 77 +/- 12 to 70 +/- 8 beats/min. Plasma renin activity and plasma aldosterone showed only minor changes. Nausea, heavy dreams, facial and hand flushing and mild depression were reported as side effects. In most patients the symptoms disappeared without reduction in the dose. In one patient anaemia developed after 7 weeks and treatment with prizidilol was stopped. A slight but statistically significant decrease in haemoglobin concentration of 1.1 +/- 0.6 g/dl was observed in 5 of the 10 patients (p less than 0.02). Thus, a mean dose of prizidilol of 410 +/- 242 mg/day had a mean blood pressure lowering effect of 24/12 mmHg. In 7 of the 10 patients (70%) diastolic blood pressure could be reduced to 95 mmHg or less. However, the observed haematological side-effects should be carefully monitored in further studies and may limit the clinical use of prizidilol.

show abstract

Effects of SK & F 92657 on the superficial hand veins and forearm arterioles of man [proceedings]

Cited by 5 publications

References 3 publications

Clinical pharmacology, physiology and pathophysiology of superficial veins‐2.

Clinical pharmacology, physiology and pathophysiology of superficial veins‐2.

Prizidilol, a combined vasodilatory and β-adrenoceptor blocking drug, in primary hypertension

Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension

Contact Info

Product

Resources

About